Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: Dual inhibitors of EGFR and Src protein tyrosine kinases

被引:36
作者
Lin, Jinsheng [1 ]
Shen, Wei [1 ]
Xue, Jingwei [1 ]
Sun, Juan [1 ]
Zhang, Xue [1 ]
Zhang, Can [1 ]
机构
[1] China Pharmaceut Univ, Ctr Drug Discovery, State Key Lab Nat Med, Nanjing 210009, Peoples R China
关键词
Protein tyrosine kinases (PTK); Anti-tumor agents; EGFR inhibitor; Src inhibitor; Oxazolo[4,5-g]quinazolin-2(1H)-one scaffold; GROWTH-FACTOR RECEPTOR; NEUTRAL; 5-SUBSTITUTED; 4-ANILINOQUINAZOLINES; ORALLY-ACTIVE INHIBITORS; IRREVERSIBLE INHIBITORS; POTENT; CANCER; EXPRESSION; BINDING;
D O I
10.1016/j.ejmech.2012.06.055
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Quinazoline-containing derivatives are an important class of synthetic products and represent an attractive scaffold for EGFR inhibitors. A series of oxazolo[4,5-g]quinazolin-2(1H)-one derivatives were synthesized and the EGFR and Src inhibition activities were evaluated using Gefitinib as lead compound. The three most potent compounds 5y, 51 and 5a each inhibited EGFR at the IC50 value of 61 nM, 67 nM and 78 nM. Among them, 5c also demonstrated excellent inhibition activity against Src with the IC50 value of 3.1 mu M. Several of these derivatives also showed good anti-proliferation effects against KB and A498 cells. (C) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:39 / 48
页数:10
相关论文
共 20 条
  • [1] Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy
    Ang, KK
    Andratschke, NH
    Milas, L
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03): : 959 - 965
  • [2] Quantitative Prediction of Fold Resistance for Inhibitors of EGFR
    Balius, Trent E.
    Rizzo, Robert C.
    [J]. BIOCHEMISTRY, 2009, 48 (35) : 8435 - 8448
  • [3] Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
    Ballard, Peter
    Barlaam, Bernard C.
    Bradbury, Robert H.
    Dishington, Allan
    Hennequin, Laurent F. A.
    Hickinson, D. Mark
    Hollingsworth, Ian M.
    Kettle, Jason G.
    Klinowska, Teresa
    Ogilvie, Donald J.
    Pearson, Stuart E.
    Scott, James S.
    Suleman, Abid
    Whittaker, Robin
    Williams, Emma J.
    Wood, Robin
    Wright, Lindsay
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) : 6326 - 6329
  • [4] A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
    Barlaam, Bernard
    Ballard, Peter
    Bradbury, Robert H.
    Ducray, Richard
    Germain, Herve
    Hickinson, D. Mark
    Hudson, Kevin
    Kettle, Jason G.
    Klinowska, Teresa
    Magnien, Francoise
    Ogilvie, Donald J.
    Olivier, Annie
    Pearson, Stuart E.
    Scott, James S.
    Suleman, Abid
    Trigwell, Cath B.
    Vautier, Michel
    Whittaker, Robin D.
    Wood, Robin
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (02) : 674 - 678
  • [5] Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
  • [6] Novel Substituted Quinazolines for Potent EGFR Tyrosine Kinase Inhibitors
    Cruz-Lopez, O.
    Conejo-Garcia, A.
    Nunez, M. C.
    Kimatrai, M.
    Garcia-Rubino, M. E.
    Morales, F.
    Gomez-Perez, V.
    Campos, J. M.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2011, 18 (07) : 943 - 963
  • [7] Mechanism of action of erbB tyrosine kinase inhibitors
    Fry, DW
    [J]. EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) : 131 - 139
  • [8] Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
    Hirsch, FR
    Varella-Garcia, M
    Bunn, PA
    Di Maria, MV
    Veve, R
    Bremnes, RM
    Barón, AE
    Zeng, C
    Franklin, WA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3798 - 3807
  • [9] ERBB receptors and cancer: The complexity of targeted inhibitors
    Hynes, NE
    Lane, HA
    [J]. NATURE REVIEWS CANCER, 2005, 5 (05) : 341 - 354
  • [10] Tyrosine kinase inhibitors.: 19.: 6-alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors
    Klutchko, SR
    Zhou, HR
    Winters, RT
    Tran, TP
    Bridges, AJ
    Althaus, IW
    Amato, DM
    Elliott, WL
    Ellis, PA
    Meade, MA
    Roberts, BJ
    Fry, DW
    Gonzales, AJ
    Harvey, PJ
    Nelson, JM
    Sherwood, V
    Han, HK
    Pace, G
    Smaill, JB
    Denny, WA
    Showalter, HDH
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (04) : 1475 - 1485